These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25571620)

  • 21. [New antibiotics - standstill or progress].
    Rademacher J; Welte T
    Med Klin Intensivmed Notfmed; 2017 Apr; 112(3):206-213. PubMed ID: 28314920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tedizolid: a novel oxazolidinone for Gram-positive infections.
    Moellering RC
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S1-3. PubMed ID: 24343826
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
    Quist SR; Fierlbeck G; Seaton RA; Loeffler J; Chaves RL
    Int J Antimicrob Agents; 2012 Jan; 39(1):90-1. PubMed ID: 21982144
    [No Abstract]   [Full Text] [Related]  

  • 24. New antibiotics in the management of acute bacterial skin and skin structure infections.
    Gleghorn K; Grimshaw E; Kelly EK
    Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacies of Tedizolid Phosphate, Linezolid, and Vancomycin in a Murine Model of Subcutaneous Catheter-Related Biofilm Infection Due to Methicillin-Susceptible and -Resistant Staphylococcus aureus.
    Bayer AS; Abdelhady W; Li L; Gonzales R; Xiong YQ
    Antimicrob Agents Chemother; 2016 Aug; 60(8):5092-6. PubMed ID: 27297485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
    McCurdy SP; Jones RN; Mendes RE; Puttagunta S; Dunne MW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5007-9. PubMed ID: 25987636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
    Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
    Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.
    Chahine EB; Sucher AJ; Knutsen SD
    Consult Pharm; 2015 Jul; 30(7):386-94. PubMed ID: 26173190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy.
    Cojutti P; Scarparo C; Sartor A; Coato P; Rigoli R; Pea F
    Diagn Microbiol Infect Dis; 2015 Jan; 81(1):53-6. PubMed ID: 25301716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Staphylococcus aureus and antibiotic resistance].
    Sancak B
    Mikrobiyol Bul; 2011 Jul; 45(3):565-76. PubMed ID: 21935792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
    Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New treatments for methicillin-resistant Staphylococcus aureus.
    Stryjewski ME; Corey GR
    Curr Opin Crit Care; 2009 Oct; 15(5):403-12. PubMed ID: 19561492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.
    Burdette SD; Trotman R
    Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial agents in treatment of MRSA infections.
    Johnson MD; Decker CF
    Dis Mon; 2008 Dec; 54(12):793-800. PubMed ID: 18996282
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin approved for acute skin infections.
    Traynor K
    Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
    [No Abstract]   [Full Text] [Related]  

  • 38. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Guzek A; Rybicki Z; Tomaszewski D
    Indian J Med Microbiol; 2018; 36(1):119-120. PubMed ID: 29735840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.